

**Methods:** A systematic review based on publications from PubMed, Embase and PsycInfo

**Results:** The etiology of MDD can be understood as sliding down a spiral. This stress spiralling mechanism can be promoted or inhibited by: 1.factors such as a poor lifestyle or (pre-existing) illness 2.bettering someone's lifestyle, coping behavior or providing pro-/prebiotics in combination with personalised therapeutics.

**Conclusions:** We argue that an interdisciplinary One Health approach is the most promising preventive and therapeutic option for MDD.

**Disclosure:** No significant relationships.

**Keywords:** HPA axis; pro-inflammatory state; microbiota; MDD

## EPV0652

### Effectiveness of vortioxetine in real-world clinical practice: French cohort results from the global RELIEVE study

M. Polosan<sup>1</sup>, M. Rabbani<sup>2\*</sup>, K. Simonsen<sup>3</sup> and H. Ren<sup>3</sup>

<sup>1</sup>GIN, Inserm U836, Grenoble, France; <sup>2</sup>Lundbeck France, Medical Affairs, Paris, France and <sup>3</sup>H.Lundbeck A/S, Medical Affairs, Valby, Denmark

\*Corresponding author.

doi: 10.1192/j.eurpsy.2022.1454

**Introduction:** Major depressive disorder (MDD) affects around 10% of the French population annually and significantly impacts patient functioning. Efficacy of vortioxetine was demonstrated in randomised controlled trials, data on its real-world performance is needed.

**Objectives:** To describe the effectiveness and safety of vortioxetine in real-world setting from patients enrolled from France in the global RELIEVE study.

**Methods:** RELIEVE was a prospective, multi-national, observational study of outpatients initiating vortioxetine treatment for MDD at physician's discretion. Data were collected at routine clinical visits. Here we present the outcomes of treatment of patients in France. The primary outcome was functioning measured by SDS. Secondary outcomes included depressive symptoms measured by PHQ-9, cognitive symptoms measured by PDQ-5 and DSST. Changes from baseline to month 6 were estimated with a linear mixed model of repeated measures approach.

**Results:** A total of 184 patients (mean age, 50.2 years, 65% female, 67.9% of patients had at least one comorbidity) were enrolled from France and included in the analysis. Mean(SD) SDS total score, PHQ-9, PDQ-5 scores at baseline were 21.1(5.4), 17.5(4.7) and 11.7(4.4), the scores(SE) decreased by 10.9(0.59), 9.3(0.48) and 6.1(0.37) from baseline to month 6. Mean(SD) DSST improved from 41.6(15.2) at baseline to 49.1(19.0) at month 6. Safety and tolerability profile of vortioxetine was in line with previous studies.

**Conclusions:** Sustained improvements in overall functioning, depressive symptoms, cognitive function were observed in patients treated with vortioxetine in a real-world setting, which provided further evidence of effectiveness and safety of vortioxetine in a broad MDD population in France.

**Disclosure:** M. Rabbani is an employee of Lundbeck France. K. Simonsen and H. Ren are employees of H. Lundbeck A/S.

**Keywords:** real world evidence; vortioxetine; Depression; effectiveness

## e-Mental Health

### EPV0653

### Integration of real-world clinical data into the Munich Mental Health Biobank – clinical and scientific potential and challenges

J. Kálmán<sup>1\*</sup>, G. Burkhardt<sup>1</sup>, O. Pogarell<sup>1</sup>, F. Padberg<sup>1</sup>, T. Schulze<sup>2</sup> and P. Falkai<sup>1</sup>

<sup>1</sup>University Hospital, LMU Munich, Department Of Psychiatry And Psychotherapy, Munich, Germany and <sup>2</sup>University Hospital, LMU Munich, Institute Of Psychiatric Phenomics And Genomics, Munich, Germany

\*Corresponding author.

doi: 10.1192/j.eurpsy.2022.1455

**Introduction:** New insights into the pathophysiology of mental disorders and innovations in psychiatric care depend on the availability of representative, longitudinal and multidimensional datasets across diverse, transdiagnostic populations. Biobanks usually attempt to collect such data in parallel to clinical routine, which is resource-intensive, puts additional burden on health-care providers, and may reduce the generalizability of the results. Despite containing rich phenotypic and biological information, data generated in routine clinical care is seldomly used for research purposes, because it is usually unstructured and locked in data silos. To truly link clinical practice and research, solutions that optimize the generation and scientific utilization of real-world clinical data are needed.

**Objectives:** Evaluation of a new digital infrastructure which warrants the efficient, automatized, and structured collection of real-world data in psychiatric care, and integrates the generated data into existing biobanking efforts.

**Methods:** We have developed a new documentation system which augments the existing IT-structures, enables the collection of routine clinical data in a structured format and involves patients in the data generation process. In an implementation science approach, to replicate and extend the findings of Blitz et al. (JMIR Ment Health 2021), we are investigating the acceptance, efficacy, and safety of the system in our outpatient clinic for affective disorders.

**Results:** First results describing the technical safety, usage metrics, and acceptance of the system, and the quality of the collected data will be presented.

**Conclusions:** Challenges of collecting real-world data for biobanking and research purposes and perspectives on future digital solutions will be discussed.

**Disclosure:** No significant relationships.

**Keywords:** digitalization; biobank; real-world data; affective disorders

### EPV0654

### Mental Health and Information Reporting Assistant: technological innovation including low- and middle-income countries - an update

R. Zimmermann

University of Basel, Faculty For Psychology, Basel, Switzerland

doi: 10.1192/j.eurpsy.2022.1456